Why invest
Our vision is to make MOB-015, launched in Sweden and Norway under the brand name Terclara®, the leading nail fungus treatment globally, and to build a specialty pharmaceutical company with our own sales in the U.S. and sales through partners in other markets.
World-leading anti-fungal effect
- 76% of the patients became fungus-free in two phase 3 studies that included over 800 patients
- MOB-015 is a topical formulation of terbinafine. 1000 times lower concentration of terbinafine in the blood compared to oral treatment.
- Strong premium position from true competitive advantage: Targeting category leadership with USD 250-500m potential global product sales
Strong commercial partners in place
Europa, APAC, China
Scandinavia
Canada
Israel
Market leader in nail fungus
- Terclara® became the market leader in Sweden and Norway instantly after starting consumer marketing
- National marketing authorization approvals received in 13 European countries, whereof 7 granted OTC status. The rollout is ongoing together with Karo Healthcare.
- Builds on previous successes with the first-generation product Kerasal Nail®/Nalox®, which was sold for 1.4 billion SEK
Significant events during the latest quarter
- On April 24, the company announced that Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zeeland, South Korea and Taiwan
- On June 8, the company announced that Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China
Share Price
Calendar
Latest Press Releases